- Home
- WLYB vs CLDX Comparison
WLYB vs CLDX Comparison
Compare WLYB & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLYB | CLDX |
|---|---|---|
| Founded | 1807 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 1994 | 1995 |
Fundamental Metrics
Financial Performance| Metric | WLYB | CLDX |
|---|---|---|
| Price | $48.00 | $39.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | 256.0 | ★ 661.9K |
| Earning Date | 06-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ 171.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,796,103,000.00 | $12,743,000.00 |
| Revenue This Year | $1.04 | $111.39 |
| Revenue Next Year | $2.36 | $235.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.51 | ★ 87.78 |
| 52 Week Low | $29.16 | $22.10 |
| 52 Week High | $55.51 | $45.14 |
Technical Indicators
Market Signals| Indicator | WLYB | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 38.13 |
| Support Level | $36.32 | $28.51 |
| Resistance Level | $53.65 | $40.30 |
| Average True Range (ATR) | 0.71 | 1.21 |
| MACD | -0.83 | -0.47 |
| Stochastic Oscillator | 0.00 | 8.52 |
Price Performance
Historical ComparisonAbout WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.